|
Medivation motivates medicine makers. The company acquires, develops, and sells (or partners with companies working on) early-development stage biopharmaceuticals. Medivation initiates drug development programs, seeking out candidates that address unmet medical needs and have the potential to rapidly enter clinical development and marketing stages. Medivation typically develops its drug candidates through early stage clinical trials, and then determines whether to conduct further studies or to seek a partner or buyer to continue later-stage trials. Included in Medivation's current pipeline are therapies addressing Alzheimer's and Huntington's diseases and hormone-refractory prostate cancer.
|
| | | Contact Information | |
Address: |
201 Spear St., 3rd Fl.
San Francisco, CA 94105
| | Phone: | 415-543-3470 | | Fax: | 415-543-3411 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 12.60 M | | Employees (2008): | 59 |
|
|
Key People
| | • |
Chairman:
Kim D. Blickenstaff
| | • |
President, CEO, and Director:
David T. Hung
| | • |
SVP, CFO, and Corporate Secretary:
C. Patrick Machado
|
|
|
